Figure 1.

Reduced SIRT1 expression and activity in GD patients. (A) The levels of SIRT1 mRNA in PBMCs were detected by qRT-PCR from 51 GD patients and 30 HCs. (B) Western blotting analysis of SIRT1 expression in GD patients and HC PBMCs (n = 4). (C) Representative images of immunofluorescence of SIRT1 (green) in GD patients and HC PBMCs. Nuclei were stained with DAPI (blue) (n = 5). Scale bars, 20 μm. (D) Total SIRT1 activity was determined in GD patients and HC PBMCs (n = 7). (E) Representative immunohistochemistry staining for SIRT1 in the thyroids of patients with GD and HCs (n = 3). Scale bars, 20 μm. GD, Graves’ disease; HC, healthy control. Data represent means ± s.e.m. *P < 0.05.